Press Releases

March 23, 2017
FDA Provides Cornerstone Pharmaceuticals Approval to Initiate Pivotal Study for CPI-613, its Metabolism-Directed Anticancer Compound

February 08, 2017
Cornerstone Pharmaceuticals, Inc. Announces the Addition of World-Renowned Experts to Scientific and Medical Advisory Boards

January 10, 2017
Cornerstone Pharmaceuticals, Inc. Announces Additions to its Board of Directors: Jean-Pierre Sommadossi, Ph.D., Richard Axel, M.D., Chi Van Dang, M.D., Ph.D., and Richard Scheller, Ph.D.

December 22, 2016
Cornerstone Pharmaceuticals to Present at 9th Annual Biotech Showcase™ in San Francisco, January 9-11, 2017

December 05, 2016
Cornerstone Pharmaceuticals, Inc. Presents Phase I Data on CPI-613 in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkin’s Lymphoma (T-cell NHL) at ASH 2016

November 29, 2016
Cornerstone Pharmaceuticals Appoints Brian Mullaney, M.D., Ph.D., as Chief Medical Officer

November 21, 2016
Cornerstone Pharmaceuticals to Present New Data on CPI-613 at the American Society of Hematology 2016 Annual Meeting

November 10, 2016
IDT Corporation Announces Investment in Cornerstone Pharmaceuticals

October 06, 2016
European Society for Medical Oncology (ESMO) Congress 2016 has Accepted the Abstract on Phase I Trial of CPI-613 in Combination with Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin (mFOLFIRINOX) in First Line Patients with Metastatic Pancreatic Adenocarcinoma

September 26, 2016
Cornerstone Pharmaceuticals Inc at Ladenburg Thalmann 2016 Healthcare Conference
Event Details: Tuesday, September 27, 2016

February 05, 2016
Cornerstone Pharmaceuticals Inc at Leerink Partners 5th Annual Global Healthcare Conference
Event Details: Wednesday, February 10, 2016 11:55 a.m. ET

January 22, 2016
Phase I Trial Data for Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin (mFOLFIRINOX) in Metastatic Pancreatic Adenocarcinoma to Be Presented at the Annual Gastrointestinal Cancers Symposium

November 23, 2015
Phase I Trial Data for Cornerstone Pharmaceuticals’ CPI-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone in Relapsed or Refractory Acute Myeloid Leukemia to Be Presented at 57th Annual ASH Meeting

January 21, 2015
Cornerstone Pharmaceuticals Receives Funding through New Jersey’s Technology Business Tax Certificate Transfer Program

January 12, 2015
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Metastatic Colorectal Cancer

December 05, 2014
Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613 for the Treatment of B-Cell Non-Hodgkin Lymphoma

November 13, 2014
Cornerstone Pharmaceuticals’ CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting Oncology Projects to Watch

November 06, 2014
Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be Presented at 2014 ASH Annual Meeting

October 21, 2014
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin’s or T-Cell Non-Hodgkin’s Lymphoma

October 09, 2014
Cornerstone Pharmaceuticals Appoints Steve Carchedi Chief Executive Officer

October 07, 2014
Cornerstone Pharmaceuticals’ CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR’s Clinical Cancer Research

May 14, 2014
Cornerstone Pharmaceuticals Clinical Data on CPI-613 to be Presented at ASCO 2014

April 18, 2014
Cornerstone Pharmaceuticals’ CPI-613 Data to be Presented at the 2014 Annual American Society of Clinical Oncology (ASCO) Meeting


March 12, 2014
Cornerstone Pharmaceuticals Lead Compound CPI-613 Demonstrates Ability to Disrupt Growth of Cancer Cells

February 28, 2014
Cornerstone Pharmaceuticals Presents Non-Small Cell Lung Cancer Data for CPI-613 at 2014 Special Conference of American Association for Cancer Research

January 31, 2014
Cornerstone Pharmaceuticals Appoints Dr. Chi Van Dang to Scientific Advisory Board

December 09, 2013
Cornerstone Pharmaceuticals Presents Updated Phase I Data for CPI-613 at 2013 American Society of Hematology Annual Meeting

November 13, 2013
Cornerstone Pharmaceuticals to Present on Cancer Metabolism at Target TME 2013 Workshop

November 11, 2013
Cornerstone Pharmaceuticals to Present CPI-613 Phase I Results at 2013 American Society of Hematology Annual Meeting

October 31, 2013
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 in Patients with Locally Advanced or Metastatic Pancreatic Cancer

October 24, 2013
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell Lung Cancer

October 03, 2013
Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for Treatment of Myelodysplastic Syndrome

September 25, 2013
Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 for the Treatment of Myelodysplastic Syndrome


August 12, 2013
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Acute Myelogenous Leukemia

August 08, 2013
Cornerstone Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613 for the Treatment of Advanced Bile Duct Cancers

June 03, 2013
Cornerstone Pharmaceuticals Presents Data at 2013 Annual ASCO Meeting

May 23, 2013
Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 in Patients with Advanced Solid Tumors

April 30, 2013
Cornerstone Pharmaceuticals Appoints Dr. Sim Fass and Howard Jonas to Board of Directors

April 22, 2013
Cornerstone Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613 with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer

September 28, 2012
Cornerstone Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at the Tenth Annual Discovery On Target Conference in Boston regarding cancer cell metabolism

September 24, 2012
Cornerstone Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at BioX 2012 Conference

June 01, 2012
Cornerstone Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613 at 2012 Annual ASCO Meeting

April 30, 2012
Cornerstone Pharmaceuticals announces publication of case report on treatment of a patient presenting metastatic pancreatic cancer with CPI-613 and gemcitabine combination therapy


April 02, 2012
Cornerstone Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613 at 2012 Annual AACR Meeting

December 12, 2011
Cornerstone Pharmaceuticals’ cancer metabolism inhibitor, CPI-613, showing promise in Phase I trial for acute myeloid leukemia

October 26, 2011
Cornerstone Pharmaceuticals to present at the 9th Annual Discovery on Target Meetings in Boston

September 15, 2011
Cornerstone Pharmaceuticals publishes positive pre-clinical study results comparing its proprietary drug EmPAC™ to Taxol® in the Journal of Nanoscience and Nanotechnology

September 06, 2011
Cornerstone Pharmaceuticals announces FDA orphan drug designation of CPI-613 for patients with acute myeloid leukemia

July 25, 2011
Cornerstone Pharmaceuticals announces the Journal of Molecular Medicine’s publication of research showing selective inhibition of cancer cell energy metabolism with its novel lipoate derivative compounds

June 03, 2011
Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia

March 14, 2011
Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study

November 05, 2010
Cornerstone Pharmaceuticals Awarded $490K in Grants Under QTDP Program

October 11, 2010
Cornerstone Pharmaceuticals Presents Interim Phase I Data at the European Society of Medical Oncology Annual Conference

 


September 09, 2010
Dr. Robert Shorr, Leading Scientist in Cancer Metabolism, to Speak at Two Upcoming Pharmaceutical Conferences

August 17, 2010
Cornerstone Pharmaceuticals Appoints Dr. Dorit Arad Director of Research and Development for its Israeli Operations

August 05, 2010
Cornerstone Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First-in-Class Anti-Cancer Agent CPI-613

June 07, 2010
Cornerstone Pharmaceuticals Appoints Timothy Sullivan Executive Vice President and Head of Corporate Development

April 19, 2010
Cornerstone Pharmaceuticals Partners with Wake Forest University on Clinical Trial of CP-613 for Hematologic Malignancies

March 22, 2010
Cornerstone Pharmaceuticals Enters Into a Collaboration Agreement with the U.S. National Cancer Institute

March 08, 2010
Dr. Robert Shepard Appointed Chief Medical Officer for Cornerstone Pharmaceuticals

February 08, 2010
Cornerstone Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First- In-Class Anti-Cancer Agent CPI-613

November 11, 2009
Cornerstone Pharmaceuticals Chosen Among Top 10 Most Interesting Oncology Projects

November 04, 2009
Leading Oncologist Dr. Robert Shepard Joins Cornerstone Pharmaceuticals as Acting Chief Medical Officer


October 05, 2009
Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D., to its Scientific Advisory Board

May 27, 2009
Cornerstone Pharmaceuticals Announces $6M Financing to Further Advance Clinical Trials in Cancer Patients

May 27, 2009
Cornerstone Pharmaceuticals Initiates Phase I/II Combination Therapy Clinical Trial of CPI-613 for Treatment of Pancreatic Cancer

September 24, 2008
Cornerstone Pharmaceuticals Announces Initiation of Clinical Trials of CPI-613 for the Treatment of Cancer

July 24, 2008
Cornerstone Pharmaceuticals Announces Approval to Conduct Phase I / II Clinical Trial of CPI-613 in Cancer Patients by US FDA